NVP015
NVP015 is a program aimed at developing a systemic treatment for patients with genetic mitochondrial neurological diseases such as Leigh syndrome, and MELAS (mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes). Developed by the mitochondrial medicine company NeuroVive Pharmaceutical, the NVP015 program’s lead compound has produced positive results…